Iovance Biotherapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference Read more about Iovance Biotherapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
Iovance Biotherapeutics to Participate at November Investor Conferences Read more about Iovance Biotherapeutics to Participate at November Investor Conferences
Iovance Biotherapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update Read more about Iovance Biotherapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting Read more about Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
Iovance Biotherapeutics to Host Third Quarter 2018 Financial Results Conference Call and Webcast on Tuesday, November 6, 2018 Read more about Iovance Biotherapeutics to Host Third Quarter 2018 Financial Results Conference Call and Webcast on Tuesday, November 6, 2018
Iovance Biotherapeutics to Host Melanoma Program Update Event for Analysts and Investors During SITC 2018 Read more about Iovance Biotherapeutics to Host Melanoma Program Update Event for Analysts and Investors During SITC 2018
Iovance Biotherapeutics and MaSTherCell Announce New Manufacturing Services Agreement in Europe Read more about Iovance Biotherapeutics and MaSTherCell Announce New Manufacturing Services Agreement in Europe
Iovance Biotherapeutics, Inc. Announces Closing of $252 Million Common Stock Public Offering Read more about Iovance Biotherapeutics, Inc. Announces Closing of $252 Million Common Stock Public Offering
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $220 Million of Common Stock Read more about Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $220 Million of Common Stock
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock Read more about Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock